These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 27927042)

  • 41. [Driving under the influence of amphetamine and metamphetamine].
    Lia K; Spigset O; Slørdal L
    Tidsskr Nor Laegeforen; 2009 Jan; 129(2):105-8. PubMed ID: 19151802
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of methamphetamine abuse beyond individual users.
    Watanabe-Galloway S; Ryan S; Hansen K; Hullsiek B; Muli V; Malone AC
    J Psychoactive Drugs; 2009 Sep; 41(3):241-8. PubMed ID: 19999677
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The epidemiology of methamphetamine use and harm in Australia.
    Degenhardt L; Roxburgh A; Black E; Bruno R; Campbell G; Kinner S; Fetherston J
    Drug Alcohol Rev; 2008 May; 27(3):243-52. PubMed ID: 18368605
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992-2007.
    Maxwell JC; Rutkowski BA
    Drug Alcohol Rev; 2008 May; 27(3):229-35. PubMed ID: 18368603
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research.
    Stoops WW; Rush CR
    Expert Rev Clin Pharmacol; 2014 May; 7(3):363-74. PubMed ID: 24716825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of Wisconsin Card Sorting Test results between Czech subjects dependent on methamphetamine versus healthy volunteers.
    Hosak L; Preiss M; Bazant J; Tibenska A; Cermakova R; Cermakova E
    Psychiatr Danub; 2012 Jun; 24(2):188-93. PubMed ID: 22706418
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacotherapy for methamphetamine dependence: a review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions.
    Rose ME; Grant JE
    Ann Clin Psychiatry; 2008; 20(3):145-55. PubMed ID: 18633741
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The methamphetamine epidemic and dentistry.
    Klasser GD; Epstein JB
    Gen Dent; 2006; 54(6):431-9; quiz 440, 448. PubMed ID: 17134084
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Methamphetamine abuse: medical and dental considerations.
    Smart RJ; Rosenberg M
    J Mass Dent Soc; 2005; 54(2):44-6, 48-9. PubMed ID: 16149403
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Methamphetamine and its impact on dental care.
    Klasser GD; Epstein J
    J Can Dent Assoc; 2005 Nov; 71(10):759-62. PubMed ID: 16324229
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of methamphetamine abuse: research findings and clinical directions.
    Cretzmeyer M; Sarrazin MV; Huber DL; Block RI; Hall JA
    J Subst Abuse Treat; 2003 Apr; 24(3):267-77. PubMed ID: 12810148
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Review of Methamphetamine Dependence and Withdrawal Treatment: A Focus on Anxiety Outcomes.
    Hellem TL
    J Subst Abuse Treat; 2016 Dec; 71():16-22. PubMed ID: 27776672
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cholinesterase inhibitors might alleviate methamphetamine-induced delusions, hallucinations and cognitive impairment, while reducing craving and addiction.
    Alisky JM
    World J Biol Psychiatry; 2006; 7(4):269. PubMed ID: 17071550
    [No Abstract]   [Full Text] [Related]  

  • 54. The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study.
    Ray LA; Bujarski S; Courtney KE; Moallem NR; Lunny K; Roche D; Leventhal AM; Shoptaw S; Heinzerling K; London ED; Miotto K
    Neuropsychopharmacology; 2015 Sep; 40(10):2347-56. PubMed ID: 25801501
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacotherapy of methamphetamine addiction: an update.
    Elkashef A; Vocci F; Hanson G; White J; Wickes W; Tiihonen J
    Subst Abus; 2008; 29(3):31-49. PubMed ID: 19042205
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Technology and innovation in the psychosocial treatment of methamphetamine use, risk and dependence.
    Kay-Lambkin FJ
    Drug Alcohol Rev; 2008 May; 27(3):318-25. PubMed ID: 18368614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prosthodontics treatment considerations for methamphetamine-dependent patients.
    Gantos MA; Manzotti A; Yuan JC; Afshari FS; Marinis A; Syros G; Rynn MH; Sukotjo C
    J Prosthodont; 2015 Jan; 24(1):64-70. PubMed ID: 25627552
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment.
    Volz TJ; Fleckenstein AE; Hanson GR
    Addiction; 2007 Apr; 102 Suppl 1():44-8. PubMed ID: 17493052
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neurofeedback Training as a New Method in Treatment of Crystal Methamphetamine Dependent Patients: A Preliminary Study.
    Rostami R; Dehghani-Arani F
    Appl Psychophysiol Biofeedback; 2015 Sep; 40(3):151-61. PubMed ID: 25894106
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting mGlu
    Petzold J; Szumlinski KK; London ED
    Pharmacol Ther; 2021 Aug; 224():107831. PubMed ID: 33705840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.